These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

154 related articles for article (PubMed ID: 39188100)

  • 1. Germline BRCA1-Mutated Synchronous and Metachronous Pancreatic Acinar Cell Carcinoma With Long-Term Survival.
    Kubo T; Ikeda Y; Muramatu J; Ishikawa K; Yoshida M; Kukita K; Imamura M; Sugita S; Sakurai A; Takada K
    Cancer Rep (Hoboken); 2024 Aug; 7(8):e70007. PubMed ID: 39188100
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A case of BRCA1-mutated giant pancreatic acinar cell carcinoma successfully treated with modified FOLFIRINOX therapy and radical resection.
    Watanabe T; Nagaoka Y; Kimura N; Fukasawa M; Shirai Y; Hirano K; Shibuya K; Yoshioka I; Hamashima T; Fujii T
    Clin J Gastroenterol; 2024 Oct; 17(5):970-975. PubMed ID: 38836973
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pathological complete response with FOLFIRINOX therapy for recurrence of pancreatic acinar cell carcinoma.
    Teramatsu K; Fujimori N; Murakami M; Yasumori S; Matsumoto K; Nakata K; Nakamura M; Koga Y; Oda Y; Ogawa Y
    Clin J Gastroenterol; 2024 Aug; 17(4):776-781. PubMed ID: 38761340
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pancreatic acinar cell carcinoma is associated with
    Kryklyva V; Haj Mohammad N; Morsink FHM; Ligtenberg MJL; Offerhaus GJA; Nagtegaal ID; de Leng WWJ; Brosens LAA
    Cancer Biol Ther; 2019; 20(7):949-955. PubMed ID: 31002019
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Exceptional Response of Pancreatic Acinar Cell Carcinoma and Bile Duct Cancer to Platinum-Based Chemotherapy in a Family With a Germline BRCA2 Variant.
    Sunami T; Yamada A; Kondo T; Kanai M; Nagai K; Uchida Y; Yokode M; Matsumori T; Uza N; Murakami H; Yamada T; Muto M
    Pancreas; 2022 Oct; 51(9):1258-1262. PubMed ID: 37078954
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The response of pancreatic acinar cell carcinoma to platinum and olaparib therapy in a germline BRCA2 variant carrier: case report and literature review.
    Matsubayashi H; Todaka A; Tsushima T; Kiyozumi Y; Harada R; Ishihara E; Higashigawa S; Ohike N; Sakamoto H; Sato J; Ishiwatari H; Sugiura T; Uesaka K
    Fam Cancer; 2024 Aug; 23(3):393-398. PubMed ID: 38733420
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Response of germline BRCA2-mutated advanced pancreatic acinar cell carcinoma to olaparib: A case report.
    Li M; Mou Y; Hou S; Cao D; Li A
    Medicine (Baltimore); 2018 Nov; 97(45):e13113. PubMed ID: 30407325
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Germline BRCA2 variants in advanced pancreatic acinar cell carcinoma: A case report and review of literature.
    Lee CL; Holter S; Borgida A; Dodd A; Ramotar S; Grant R; Wasson K; Elimova E; Jang RW; Moore M; Kim TK; Khalili K; Moulton CA; Gallinger S; O'Kane GM; Knox JJ
    World J Gastroenterol; 2022 Dec; 28(45):6421-6432. PubMed ID: 36533108
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Metastatic Acinar Cell Carcinoma of the Pancreas: A Retrospective Cohort Study on Systemic Chemotherapy and Review of the Literature.
    Busch E; Werft W; Bougatf N; Hackert T; Jäger D; Springfeld C; Berger AK
    Pancreas; 2021 Mar; 50(3):300-305. PubMed ID: 33835959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genomic Profiling Reveals Germline Predisposition and Homologous Recombination Deficiency in Pancreatic Acinar Cell Carcinoma.
    Mandelker D; Marra A; Zheng-Lin B; Selenica P; Blanco-Heredia J; Zhu Y; Gazzo A; Wong D; Yelskaya Z; Rai V; Somar J; Ostafi S; Mehta N; Yang C; Li Y; Brown DN; da Silva EM; Pei X; Linkov I; Terraf P; Misyura M; Ceyhan-Birsoy O; Ladanyi M; Berger M; Pareja F; Stadler Z; Offit K; Riaz N; Park W; Chou J; Capanu M; Koehler M; Rosen E; O'Reilly EM; Reis-Filho JS
    J Clin Oncol; 2023 Nov; 41(33):5151-5162. PubMed ID: 37607324
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy of chemotherapy combined with toripalimab in PD-L1-positive and high tumor mutation burden pancreatic acinar cell carcinoma: case report.
    Xu H; Wang X; Zhou S; Hu Q; Cao D
    Tumori; 2021 Dec; 107(6):NP24-NP27. PubMed ID: 33345750
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Modified FOLFIRINOX as a second-line therapy following gemcitabine plus nab-paclitaxel therapy in metastatic pancreatic cancer.
    Sawada M; Kasuga A; Mie T; Furukawa T; Taniguchi T; Fukuda K; Yamada Y; Takeda T; Kanata R; Matsuyama M; Sasaki T; Ozaka M; Sasahira N
    BMC Cancer; 2020 May; 20(1):449. PubMed ID: 32434547
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical characterization of patients with gBRCA1/2 mutation-positive unresectable pancreatic cancer: a multicenter prospective study.
    Kubo T; Muramatsu J; Arihara Y; Murota A; Ishikawa K; Yoshida M; Nagashima H; Tamura F; Ikeda Y; Usami M; Ono M; Nakamura H; Watanabe D; Shibata T; Kasahara K; Sakurai A; Takada K
    Jpn J Clin Oncol; 2024 Jan; 54(1):47-53. PubMed ID: 37791389
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term survival after systemic chemotherapy, chemoradiotherapy, and maintenance therapy for an older adult patient with recurrent pancreatic acinar cell carcinoma.
    Urabe M; Ikezawa K; Kozumi K; Kai Y; Takada R; Mukai K; Nakabori T; Uehara H; Akita H; Ohkawa K
    Clin J Gastroenterol; 2024 Aug; 17(4):771-775. PubMed ID: 38743170
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nab-paclitaxel plus gemcitabine versus nab-paclitaxel plus gemcitabine followed by FOLFIRINOX induction chemotherapy in locally advanced pancreatic cancer (NEOLAP-AIO-PAK-0113): a multicentre, randomised, phase 2 trial.
    Kunzmann V; Siveke JT; Algül H; Goekkurt E; Siegler G; Martens U; Waldschmidt D; Pelzer U; Fuchs M; Kullmann F; Boeck S; Ettrich TJ; Held S; Keller R; Klein I; Germer CT; Stein H; Friess H; Bahra M; Jakobs R; Hartlapp I; Heinemann V;
    Lancet Gastroenterol Hepatol; 2021 Feb; 6(2):128-138. PubMed ID: 33338442
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Treatment Outcomes Between Gemcitabine With Nab-Paclitaxel and Modified FOLFIRINOX for First-Line Chemotherapy in Metastatic and Recurrent Pancreatic Cancer: Propensity Score Matching.
    Mie T; Sasaki T; Takeda T; Fukuda K; Furukawa T; Yamada Y; Kasuga A; Matsuyama M; Ozaka M; Sasahira N
    Pancreas; 2021 Apr; 50(4):595-601. PubMed ID: 33939674
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pancreatic acinar cell carcinoma: A review on molecular profiling of patient tumors.
    Al-Hader A; Al-Rohil RN; Han H; Von Hoff D
    World J Gastroenterol; 2017 Dec; 23(45):7945-7951. PubMed ID: 29259370
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Successful conversion surgery after FOLFIRINOX therapy in a patient with advanced pancreatic acinar cell carcinoma with a solitary peritoneal dissemination: A case report.
    Uemura S; Maeda H; Tanioka N; Yamaguchi S; Munekage M; Kitagawa H; Namikawa T; Yamamoto S; Kohsaki T; Iguchi M; Uchida K; Hanazaki K
    Cancer Rep (Hoboken); 2022 Sep; 5(9):e1648. PubMed ID: 35668046
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model.
    Delahoussaye AM; Abi Jaoude J; Green M; Fujimoto TN; Molkentine J; Garcia Garcia CJ; Gay JP; Feng N; Marszalek J; Fowlkes N; Taniguchi CM
    BMC Cancer; 2022 Feb; 22(1):174. PubMed ID: 35172762
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel patient-derived xenograft mouse model for pancreatic acinar cell carcinoma demonstrates single agent activity of oxaliplatin.
    Hall JC; Marlow LA; Mathias AC; Dawson LK; Durham WF; Meshaw KA; Mullin RJ; Synnott AJ; Small DL; Krishna M; von Hoff D; Schüler J; Hart SN; Couch FJ; Colon-Otero G; Copland JA
    J Transl Med; 2016 May; 14(1):129. PubMed ID: 27165126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.